Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/ Refractory B-ALL

被引：1
|
作者：
Gauthier, Jordan [1 ,2 ]
Gazeau, Nicolas [3 ]
Fiorenza, Salvatore [4 ]
Kimble, Erik L. [4 ,5 ]
Hirayama, Alexandre Vinaud [1 ,6 ]
Pender, Barbara S. [4 ]
Di, Henna N. [3 ]
Kirchmeier, Delaney R. [4 ]
Shadman, Mazyar [4 ,7 ]
Cassaday, Ryan D. [3 ,5 ]
Riddell, Stanley R. [2 ,4 ]
Maloney, David G. [2 ,3 ]
Turtle, Cameron J. [4 ,8 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[3] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA
[4] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA
[5] Univ Washington, Dept Med, Div Hematol, Seattle, WA USA
[6] Univ Washington, Dept Med Oncol, Seattle, WA USA
[7] Univ Washington, Div Hematol & Med Oncol, Seattle, WA USA
[8] Univ Washington, Dept Med, Seattle, WA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-156822
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10360 / 10362
页数：3
相关论文
共 50 条
  • [1] Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
    Song, Fengmei
    Hu, Yongxian
    Zhang, Yanlei
    Zhang, Mingming
    Yang, Tingting
    Wu, Wenjun
    Huang, Simao
    Xu, Huijun
    Chang, Alex H.
    Huang, He
    Wei, Guoqing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [2] Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Park, Jae Hong
    Riviere, Isabelle
    Wang, Xiuyan
    Bernal, Yvette
    Purdon, Terence
    Halton, Elizabeth
    Curran, Kevin Joseph
    Sauter, Craig Steven
    Sadelain, Michel
    Brentjens, Renier J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL
    Kang, Liqing
    Ma, Jinfeng
    Lou, Xiaoyan
    Tang, Xiaowen
    Xue, Shengli
    Chen, Suning
    Qiu, Huiying
    Miao, Miao
    Han, Yue
    Wang, Ying
    Sun, Aining
    Dai, Haiping
    Xu, Yang
    Li, Limin
    Fan, Shengjin
    Qian, Chongsheng
    Gong, Wenjie
    Xu, Mingzhu
    Zhou, Haixia
    Yao, Zhen
    BLOOD, 2023, 142
  • [4] EFFICACY AND SAFETY OF CD19-TARGETED 19-28Z CAR MODIFIED T CELLS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL
    Park, J.
    Riviere, I.
    Wang, X.
    Bernal, Y.
    Purdon, T.
    Halton, E.
    Curran, K.
    Sauter, C.
    Sadelain, M.
    Brentjens, R.
    HAEMATOLOGICA, 2015, 100 : 6 - 6
  • [5] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
    Molostova, Olga
    Shelikhova, Larisa
    Muzalevsky, Yakov
    Kazachenok, Alexey
    Khismatullina, Rimma
    Abugova, Julia
    Kurnikova, Elena
    Trakhtman, Pavel
    Pershin, Dmitry
    Zubachenko, Viktoria
    Fadeeva, Maria
    Popov, Alexander M.
    Illarionova, Olga
    Miakova, Natalia
    Litvinov, Dmitry
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    BLOOD, 2021, 138
  • [6] Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients
    Tu, Sanfang
    Zhou, Lijuan
    Huang, Rui
    Zhou, Xuan
    Yang, Jilong
    He, Yanjie
    Hu, Yuxing
    Zhang, Honghao
    Xie, Xiaoling
    Li, Yuhua
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1437 - 1440
  • [7] Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy
    Davila, Marco L.
    Riviere, Isabelle
    Wang, Xiuyan
    Bartido, Shirley
    Stefanski, Jolanta
    He, Qing
    Borquez-Ojeda, Oriana
    Taylor, Clare
    Wasielewska, Teresa
    Qu, Jinrong
    Bouhassira, Diana C. G.
    Bernal, Yvette J.
    Yoo, Sarah
    Purdon, Terence
    Halton, Elizabeth
    Quintanilla, Hilda
    Park, Jae H.
    Curran, Kevin J.
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2013, 122 (21)
  • [8] Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
    Shadman, Mazyar
    Gauthier, Jordan
    Hay, Kevin A.
    Voutsinas, Jenna M.
    Milano, Filippo
    Li, Ang
    Hirayama, Alexandre V.
    Sorror, Mohamed L.
    Cherian, Sindhu
    Chen, Xueyan
    Cassaday, Ryan D.
    Till, Brian G.
    Gopal, Ajay K.
    Sandmaier, Brenda M.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD ADVANCES, 2019, 3 (20) : 3062 - 3069
  • [9] Efficacy and Safety of CD19-Targeted CAR-T Cell Therapy for Refractory/Relapsed B-Cell Lymphoma: A Single Center of Real World Data
    Huang, Jing
    Fei, Jia
    Ou, Ruiming
    Liu, Zhi
    Zheng, Liling
    Zhu, Yangmin
    Shen, Huijuan
    Du, Yuanyuan
    Zhou, Qinjun
    Chen, Jiali
    Zhou, Changhua
    Yan, Rongrong
    Wang, Jiale
    Liu, Shuang
    Zhang, Qing
    BLOOD, 2021, 138
  • [10] Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL
    Geyer, Mark Blaine
    Park, Jae H.
    Riviere, Isabelle
    Senechal, Brigitte
    Wang, Xiuyan
    Purdon, Terence J.
    Sadelain, Michel W.
    Brentjens, Renier J.
    BLOOD, 2016, 128 (22)
12345